Antibody-Based Antidiabetic Drug Development Services
Antibody therapies are at the forefront of innovation in the treatment of diabetes, providing the field with more precise, effective therapeutic options. Ace Therapeutics is committed to applying our expertise in the field of diabetes to help our clients discover and develop successful diabetes antibody therapies. Our team of experts will provide you with comprehensive solutions from target discovery to preclinical evaluation to accelerate your antidiabetic antibody therapy development program.
Introduction of Antibody-Based Antidiabetic Drugs
The intensive study of the immunopathogenesis of type 1 diabetes mellitus (T1DM) has resulted in significant advances in the development of more effective therapies for T1DM. In particular, the emergence of antibody therapies targeting T cells, B cells, and various cytokine receptors has enabled targeted immune intervention for the treatment of T1DM. Antibody therapies are designed to inhibit or mitigate destructive autoimmune processes, thereby enriching the treatment options for type 1 diabetes.
Fig. 1 mAb therapies to ameliorate type 1 diabetes (T1D). (Nagy, G.; et al., 2022)
Our Antibody-Based Antidiabetic Drug Development Services
Ace Therapeutics provides one-stop drug development services covering every key aspect of target identification, candidate screening, candidate optimization, and preclinical evaluation. Our efficient and customized services can help you save time and cost in the development of antibody-based antidiabetic drugs.
Antibody Based Antidiabetic Drug Discovery Services
- Target identification and validation
Ace Therapeutics has the ability to innovate at the source. We search for specific immune markers/targets that play a role in the development of the disease as new targets for antibody drug development in the study of diabetes pathomechanisms.
- Antibody screening and optimization
We rapidly screen antibody molecules with high affinity and specificity for target molecules from antibody libraries through antibody engineering and high-throughput screening techniques. In addition, we can optimize the screened potential antibody molecules to increase their stability and safety.
- Efficacy and safety assessment of antidiabetic antibody drug candidates
We perform preliminary assessments of key efficacy indicators of drug candidates through in vitro cellular and in vivo animal models to validate their efficacy and safety for further drug development.
Preclinical Development Services for Antibody-Based Antidiabetic Drugs
- Preclinical efficacy evaluation
We comprehensively evaluate the efficacy of potential antidiabetic antibodies in animal models of diabetes, including modulation of glucose homeostasis, stimulation of insulin secretion, and preservation of pancreatic β-cell function.
We provide customized pharmacokinetic analysis services based on the specific structural and physiological properties of antibody drugs. The absorption, distribution, metabolism and excretion of antidiabetic antibody drugs are comprehensively analyzed through in vivo animal models.
- Toxicology and safety assessment
We provide toxicological analyses such as general toxicity assessment assays, reproductive toxicity assays and immunogenicity assays to help our clients evaluate the toxicity and safety of their drug candidates.
Our Capabilities in Antibody-Based Antidiabetic Drug Development
- Diabetes mechanisms research
- In vivo and in vitro diabetes modeling
- Antibody therapy optimization
Ace Therapeutics is committed to providing comprehensive solutions to help customers discover and develop successful antidiabetic antibody drugs. Please contact us for more details and we will be happy to assist you.
References
- Ke, Q. I., et al. "Evolving antibody therapies for the treatment of type 1 diabetes." Frontiers in Immunology. 11 (2021): 624568.
- Nagy, G.; et al. "New therapeutic approaches for type 1 diabetes: Disease-modifying therapies." World Journal of Diabetes. 13.10 (2022): 835.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
